HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 386 filers reported holding HALOZYME THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.45 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $548,000 | -13.4% | 13,476 | -3.4% | 0.00% | 0.0% |
| Q2 2021 | $633,000 | +17.9% | 13,950 | +8.4% | 0.00% | 0.0% |
| Q1 2021 | $537,000 | +187.2% | 12,869 | -11.9% | 0.00% | 0.0% |
| Q1 2017 | $187,000 | -30.5% | 14,600 | -34.2% | 0.00% | 0.0% |
| Q3 2016 | $269,000 | +57.3% | 22,172 | +12.1% | 0.00% | 0.0% |
| Q2 2016 | $171,000 | -27.2% | 19,783 | -20.3% | 0.00% | 0.0% |
| Q1 2016 | $235,000 | -39.7% | 24,816 | +10.2% | 0.00% | -50.0% |
| Q4 2015 | $390,000 | +94.0% | 22,528 | +50.2% | 0.00% | +100.0% |
| Q3 2015 | $201,000 | -81.8% | 15,000 | -69.4% | 0.00% | -66.7% |
| Q2 2015 | $1,106,000 | +118.1% | 49,000 | +38.0% | 0.00% | 0.0% |
| Q1 2015 | $507,000 | +50.0% | 35,500 | +1.4% | 0.00% | +50.0% |
| Q4 2014 | $338,000 | +6.0% | 35,000 | 0.0% | 0.00% | -33.3% |
| Q3 2014 | $319,000 | -7.8% | 35,000 | 0.0% | 0.00% | 0.0% |
| Q2 2014 | $346,000 | -19.7% | 35,000 | +3.2% | 0.00% | -25.0% |
| Q1 2014 | $431,000 | – | 33,900 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Security, LLC | 7,048,282 | $126,799,000 | 27.23% |
| First Light Asset Management, LLC | 1,630,591 | $29,334,000 | 5.01% |
| SNYDER CAPITAL MANAGEMENT L P | 3,393,057 | $61,041,000 | 3.48% |
| Bellevue Group AG | 7,663,956 | $137,874,000 | 2.67% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 307,633 | $5,531,000 | 2.52% |
| Lombard Odier Asset Management (Switzerland) SA | 900,000 | $16,191,000 | 2.17% |
| Elk Creek Partners, LLC | 654,362 | $11,772,000 | 2.02% |
| DOHENY ASSET MANAGEMENT /CA | 127,110 | $2,254,000 | 1.79% |
| Granite Investment Partners, LLC | 1,277,438 | $22,981,000 | 1.49% |
| Amia Capital LLP | 69,409 | $1,249,000 | 1.11% |